Machine learning model predicts breast cancer treatment response
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...
News Medical2d
Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...
Medscape21d
Hormone Receptor (HR)–Positive, HER2-Negative Breast Cancer
"For patients receiving neoadjuvant therapy for hormone receptor‒positive, HER2-negative breast cancer, right now the standard is chemotherapy, but there are efforts looking at what other ...
technologynetworks28d
CAR T-Cell Therapy Shows Promise in Preclinical Models of HER2-Positive Solid Tumors
one third of which also express p95HER2-an altered form of the HER2 receptor-which correlates with more aggressive disease. "HER2 is arguably the most targeted receptor in the development of cancer ...
Medscape6d
The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2
Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01, 2008. The article is based primarily on a ...
EurekAlert!14d
How combining drugs may be more effective at treating HER2-positive breast cancer
HER2-positive breast cancer is a subtype of breast cancer in which breast tumor cells test positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein helps cancer ...
FiercePharma25d
Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu
Compared with the combination of Herceptin and Perjeta, Ziihera’s bispecific binding leads to unique clustering of the HER2 receptor, thereby more effectively interfering with the signaling of t ...
Medical Xpress29d
Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors
one third of which also express p95HER2—an altered form of the HER2 receptor—which correlates with more aggressive disease. "HER2 is arguably the most targeted receptor in the development of ...
clinicaltrialsarena on MSN19h
Incyclix Bio reports outcomes from breast cancer therapy trial
Incyclix Bio has reported outcomes from the dose escalation part of the Phase I/II INX-315-01 trial of INX-315 for breast cancer treatment.
News Medical on MSN4d
PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer
Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...
Targeted Oncology3d
Effective and Well-Tolerated Combo in ER+/HER2– Metastatic Breast Cancer
Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive ...